Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | THRA | P10827 | 8/20 | 0.46 |
| ▸ | THRB | P10828 | 8/20 | 0.46 |
| ▸ | CPT1A | P50416 | 1/20 | 0.45 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | SNCA | P37840 | 3/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6515485 | 0.95 | KDM4E (0.50) | KDM4ETHRATHRBCPT1ACPT1B | |
| SCHEMBL6518464 | 0.93 | KDM4E (0.48) | KDM4ETHRATHRBPPARGPPARD | |
| SCHEMBL6523621 | 0.93 | THRB (0.51) | KDM4ETHRATHRBCPT1ACPT1B | |
| SCHEMBL6511210 | 0.93 | THRA (0.53) | KDM4ETHRATHRBCPT1ACPT1B | |
| SCHEMBL6520144 | 0.91 | KDM4E (0.46) | KDM4ETHRATHRBCPT1ACPT1B | |
| SCHEMBL6516338 | 0.89 | THRA (0.50) | KDM4ETHRATHRBCPT1ACPT1B | |
| SCHEMBL6519369 | 0.88 | THRA (0.60) | KDM4ETHRATHRBCPT1ACPT1B | |
| SCHEMBL6515934 | 0.87 | KDM4E (0.49) | KDM4ETHRATHRBPPARGPPARD | |
| SCHEMBL6511409 | 0.86 | THRB (0.59) | KDM4ETHRATHRBCPT1ACPT1B | |
| SCHEMBL6515180 | 0.86 | THRB (0.53) | KDM4ETHRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050032874-A1 | Anticholesterol agents; arteriosclerosis | BAYER AKTIENGESELLSCHAFT (DE) | 2005-02-10 | — | — | US | disclosed |
| US-6794406-B2 | FOR THERAPY AND PROPHYLAXIS OF ARTERIOSCLEROSIS AND HYPERCHOLESTEROLAEMIA | BAYER AKTIENGESELLSCHAFT (DE) | 2004-09-21 | — | — | US | disclosed |
| US-20030078288-A1 | Indole derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2003-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078288-A1 | Indole derivatives | IDO1, IDO2, TPH2 | KDM4E 1199/4885THRA 2460/4885THRB 1772/4885 |
| US-20050032874-A1 | Anticholesterol agents; arteriosclerosis | HMGCR, CYP46A1, EBP | KDM4E 2994/4885THRA 1917/4885THRB 1835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.